Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea

Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea - Levofloxacin-containing sequential therapy in Korea

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015375

Enrollment

200

Registered

2014-10-08

Start date

2013-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

One group was treated with standard sequential therapy (SST) (ie, rabeprazole 20 mg twice daily + amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg twice daily + clarithromycin 500

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: dyspeptic patients aged 18-76 years with H. pylori infection

Exclusion criteria

Exclusion criteria: (1) patients with previous H. pylori eradication therapy; (2) patients treated with H2 receptor antagonist, PPI, and antibiotics in the previous 4 weeks, or nonsteroidal anti-inflammatory drug (NSAID) in the previous 2 weeks; (3) pregnant or lactating women; (4) patients who suffered from serious diseases such as severe liver disease, renal disease, and cerebrovascular disease; (5) patients who had a drug allergy to the study drugs; and (6) patients with previous gastric surgery.

Design outcomes

Primary

Measure	Time frame
Eradication rate of H pylori infection	—

Secondary

Measure	Time frame
Drug adherence and the frequency of adverse events	—

Countries

Asia(except Japan)

Contacts

Public ContactHyuk Lee

Yonsei University Dpt. of Medicine

leehyuk@skku.edu82-2-2228-1978

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026